CAR-T Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine | Biospace

Data uncovers new gene signature to help understand persistence in CAR-T cells

PLEASANTON, Calif., July 5, 2023 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single-cell and space biology, today announced that its single-cell genomic technologies are being used in a study published in the journal Medicine of Nature on new genetic signatures that explain why some children with leukemia have a longer remission after CAR T-cell therapy. The collaborative research project was led by researchers from Great Ormond Street Hospital (GOSH), the Wellcome Sanger Institute and the UCL Great Ormond Street Institute of Child Health (UCL GOS ICH).

Researchers who conducted the study, “Transcriptional Signatures Associated with Persistent CD19 CAR-T Cells in Children With Leukemia,” used chromium single-cell gene expression technologies and sample T-cell receptor sequencing to examine what makes CAR-T cells long-lived. unique. These helped identify a genetic signature of CAR-T cells that persisted in the body over the long term, an important predictor of lasting remission. The data were from the CARPALL study, which used the molecular characteristics and clonal dynamics of CAR CD19 T cells from 10 children with relapsed or refractory B-cell lymphoblasts.

Ben Hindson, co-founder and chief scientific officer of 10x Genomics, said: “Single cell genomics is a powerful tool that is transforming cancer research and our understanding of health and disease. We are so proud to have 10x technologies behind this incredible breakthrough. We celebrate the achievements of the research team and the selfless dedication of the families who made this study possible. We look forward to continuing to equip researchers with the technologies needed to fuel new biological discoveries and ultimately contribute to improve patient care”.

Using Chromium Single Cell Gene Expression products, researchers have identified a unique double negative phenotype of long-lived CAR-T cells, which provides insight into how these cells survive and remain active in the body. These key genes appeared to allow CAR-T cells to persist and thus enable children to live cancer-free long-term lives. The findings could lead to the discovery of new biomarkers that could predict the long-term duration of CAR T-cell therapies and provide better treatment options for patients.

Dr Sam Behjati, co-senior author, Group Lead and Wellcome Senior Research Fellow at the Wellcome Sanger Institute and Honorary Consultant Pediatric Oncologist at Addenbrooke’s Hospital, Cambridge, said: “This study is a fantastic step forward in our understanding of CAR T-cell persistence and illustrates the power of collaborative science and the combination of pioneering clinical research with cutting-edge genomic science.It is critical that we continue to develop and build on these new treatments to help more children with leukemia around the world “.

About 10 times the genomics
10x Genomics is a life sciences technology company that makes products to interrogate, understand and master biology to improve human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems with a resolution and scale appropriate to the complexity of biology. 10 times Genomics products have been adopted by researchers worldwide, including all 100 top global research institutions ranked by Nature in 2021 based on publications, and all top 20 global pharmaceutical companies by 2021 R&D expenditure and they have been cited in over 5,000 research articles on breakthroughs ranging from oncology to immunology and neuroscience. Our patent portfolio includes more than 1,750 issued patents and patent applications.

About the Wellcome Sanger Institute
The Wellcome Sanger Institute is a world-leading genomics research center. We undertake large-scale research that forms the foundation of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared around the world to advance science. Our ambition is vast, we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and exploit the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our discoveries are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and our blog.

Forward-Looking Statements
This news release contains forward-looking statements pursuant to the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to the “port secure” created from such sections. All statements, other than statements of historical fact, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may”, “may”, “will”, “enable”, “should”, “expect”, “plan”, “anticipate”, “may” , “intend”, “target”, “project”, “contemplate”, “believe”, “estimate”, “foresee”, “potential”, “would like”, “probably”, “seek” or “continue” or the negative aspects of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding the ability of our single cell products to transform our understanding of health and disease and improve patient care. These statements are based on current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a variety of factors. The material risks and uncertainties that could affect the financial and operating results of 10x Genomics, Inc. and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors and “Management’s discussion and analysis of financial condition and results of operations” in the company’s most recently filed 10-K filing and elsewhere in filings 10x Genomics, Inc. files from time to time with the Securities and Exchange Commission.

Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it can make no representations that such expectations will prove to be accurate nor can it guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be met or will occur. These forward-looking statements do not reflect the potential impact of any future acquisition, merger, disposition, joint venture or investment that 10x Genomics, Inc. may make. In addition, such forward-looking statements may not accurately or completely reflect that our products may be subject to regulation by the FDA or other regulatory agencies, and are available for research use only and are not intended for clinical or diagnostic uses. , and that our business depends significantly on R&D expenditures from research institutes. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of today’s date, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statement provided to reflect any change in our expectations or any change in events, conditions or circumstances upon which such statement is based, except as required by law. These forward-looking statements should not be relied upon to represent the views of 10x Genomics, Inc. as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics, Inc. uses Securities and Exchange Commission filings, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts, and our social media accounts as a means to disclose information material non-public information and to comply with our disclosure obligations under Regulation FD.

Contacts
Investors: investor@10xgenomics.com
Media: media@10xgenomics.com

View original content to download media: https://www.prnewswire.com/news-releases/car-t-cell-study-enabled-by-10x-genomics-single-cell-technology-published-in- nature-medicine -301870534.html

SOURCE 10x Genomics, Inc.

Company Codes: NASDAQ-NMS:TXG